The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

The rules over who can access weight loss jabs puts patients safety at risk, warns the National Pharmacy Association amid a boom in demand ...